NCT06973421View on ClinicalTrials.gov

Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Platinum Resistant Ovarian Cancer
Interventions
DRUG

Utidelone Capsules

60 mg/m2 orally, days 1 to 5, per cycle

DRUG

Fruquintinib Capsules

5 mg orally, days 1 to 14, per cycle

Trial Locations (1)

200032

Fudan University Shanghai Cancer Cente, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER